Ophthalmology Times.

Children and adolescents with keratoconus may have rapid progression between the ages of 8 and 19 years and immediate treatment with corneal crosslinking may stop that progression.

“When CXL initially began to be used, we always determined that the patient was progressing before CXL was applied to be sure that an emerging technology was used carefully to avoid unnecessary complications,” said Farhad Hafezi, MDPhD, who was part of the Swiss team that developed the first CXL device.

Read the article here.